Moxifloxacin (Moxifloxacin Hydrochloride)

Moxifloxacin is indicated for several bacterial infections affecting the respiratory, skin and intra‑abdominal systems.

• Community‑acquired pneumonia: effective bacterial clearance in adult patients
• Acute bacterial sinusitis: rapid resolution of sinus infection symptoms
• Acute bacterial exacerbation of chronic bronchitis: reduction of bacterial load and symptom improvement
• Skin and skin‑structure infections: eradication of susceptible pathogens
• Complicated intra‑abdominal infections: control of mixed bacterial flora in severe abdominal disease

• Moxifloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication and transcription. By binding to these enzymes, it prevents the supercoiling and unwinding of DNA, leading to bacterial cell death. The drug exhibits concentration‑dependent bactericidal activity against a broad spectrum of Gram‑positive and Gram‑negative organisms.

Moxifloxacin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset
• Diarrhea: loose stools, often self‑limiting
• Headache: transient cranial discomfort
• Dizziness: occasional vertigo or light‑headedness
• Injection site pain: local discomfort after IV administration
• Transient elevation of liver enzymes: mild hepatic enzyme rise

Serious or Rare Side Effects

• Tendon rupture: risk of tendonitis or rupture, especially in older adults
• QT interval prolongation: potential for cardiac arrhythmias
• Severe allergic reactions: anaphylaxis, Stevens‑Johnson syndrome
• Clostridioides difficile infection: colitis associated with antibiotic use
• Hepatic failure: rare but serious liver injury
• Neurological effects: seizures or peripheral neuropathy

When using Moxifloxacin, clinicians should consider several precautionary measures to minimise risk.

• Renal impairment: adjust dosing or monitor renal function closely
• Hepatic impairment: use with caution and monitor liver enzymes
• QT prolongation risk: avoid in patients with known cardiac arrhythmias or electrolyte disturbances
• Elderly patients: monitor for tendon disorders and delayed wound healing
• Concurrent fluoroquinolones: avoid combined use to reduce additive toxicity
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake

Moxifloxacin can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid)

• QT‑prolonging agents (e.g., quinidine, macrolide antibiotics): increase risk of cardiac arrhythmias
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): heightened risk of central nervous system toxicity
• Antacids containing aluminum or magnesium: may reduce systemic exposure if given concurrently

Moderate Interactions (Monitor Closely)

• Warfarin: potential alteration of INR, requiring coagulation monitoring
• Corticosteroids: increased risk of tendon rupture, especially in the elderly
• Theophylline: possible increase in serum levels, monitor for toxicity